A novel HSP90 inhibitor targeting the C-terminal domain attenuates trastuzumab resistance in HER2-positive breast cancer

Trastuzumab resistance in HER2-positive breast cancer is associated with a poorer prognosis. HSP90 is thought to play a major role in such resistance, but N-terminal inhibitors of this target have had little success. We sought to investigate the utility of NCT-547, a novel, rationally-designed C-ter...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jung Min, Kim, Yoon-Jae, Park, Soeun, Park, Minsu, Farrand, Lee, Nguyen, Cong-Truong, Ann, Jihyae, Nam, Gibeom, Park, Hyun-Ju, Lee, Jeewoo, Kim, Ji Young, Seo, Jae Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678296/
https://www.ncbi.nlm.nih.gov/pubmed/33218356
http://dx.doi.org/10.1186/s12943-020-01283-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678296/
https://www.ncbi.nlm.nih.gov/pubmed/33218356
http://dx.doi.org/10.1186/s12943-020-01283-6

Ejemplares similares